{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:03:29Z","timestamp":1793333009850,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12959-018-0161-9","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T07:37:08Z","timestamp":1516001828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-6051","authenticated-orcid":false,"given":"Hikmat","family":"Abdel-Razeq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asem","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Abdulelah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Al-Shwayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Makoseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abunasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Rimawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Al-Rabaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozan","family":"Alfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa\u2019","family":"Abufara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Bawaliz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Ismael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"issue":"10","key":"161_CR1","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712\u201323.","journal-title":"Blood"},{"issue":"10","key":"161_CR2","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/cncr.23062","volume":"110","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339\u201346.","journal-title":"Cancer"},{"issue":"2","key":"161_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/jth.12075","volume":"11","author":"A Falanga","year":"2013","unstructured":"Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11(2):223\u201333.","journal-title":"J Thromb Haemost"},{"issue":"7","key":"161_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.6004\/jnccn.2011.0064","volume":"9","author":"AA Khorana","year":"2011","unstructured":"Khorana AA. Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Cancer Netw. 2011;9(7):789\u201397.","journal-title":"J Natl Compr Cancer Netw"},{"key":"161_CR5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632\u20134.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"161_CR6","first-page":"559","volume":"9","author":"G Agnelli","year":"2014","unstructured":"Agnelli G, Verso M, Mandala M, Gallus S, Cimminiello C, Apolone G, et al. A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med. 2014;9(5):559\u201367.","journal-title":"Intern Emerg Med"},{"issue":"25","key":"161_CR7","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","volume":"343","author":"HT S\u00f8rensen","year":"2000","unstructured":"S\u00f8rensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846\u201350.","journal-title":"N Engl J Med"},{"issue":"10","key":"161_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/annonc\/mdm284","volume":"18","author":"M Mandal\u00e0","year":"2007","unstructured":"Mandal\u00e0 M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol. 2007;18(10):1660\u20135.","journal-title":"Ann Oncol"},{"key":"161_CR9","doi-asserted-by":"crossref","unstructured":"Fischer J, Ganellin CR. Analogue-based drug discovery. John Wiley & Sons. 2006. p. 513. ISBN 9783527607495.","DOI":"10.1002\/3527608001"},{"key":"161_CR10","unstructured":"WHO Model List of Essential Medicines (19th List). Available at: \n                    http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML2015_8-May-15.pdf\n                    \n                  . Accessed 01 May 2017."},{"key":"161_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1748-717X-1-14","volume":"1","author":"JC Anders","year":"2006","unstructured":"Anders JC, Grigsby PW, Singh AK. Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature. Radiat Oncol. 2006;1:14.","journal-title":"Radiat Oncol"},{"key":"161_CR12","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/S0022-5347(01)62232-8","volume":"160","author":"PM Czaykowski","year":"1998","unstructured":"Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:2021\u20134.","journal-title":"J Urol"},{"key":"161_CR13","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1200\/JCO.2000.18.10.2169","volume":"18","author":"NI Weijl","year":"2000","unstructured":"Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18:2169\u201378.","journal-title":"J Clin Oncol"},{"key":"161_CR14","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","volume":"29","author":"RA Moore","year":"2011","unstructured":"Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466\u201373.","journal-title":"J Clin Oncol"},{"issue":"1","key":"161_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12885-016-3032-4","volume":"17","author":"MN Zahir","year":"2017","unstructured":"Zahir MN, Shaikh Q, Shabbir-Moosajee M, Jabbar AA. Incidence of venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy - a cohort study. BMC Cancer. 2017;17(1):57.","journal-title":"BMC Cancer"},{"key":"161_CR16","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","volume":"30","author":"S Seng","year":"2012","unstructured":"Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous Thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012;30:4416\u201326.","journal-title":"J Clin Oncol"},{"key":"161_CR17","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902\u20137.","journal-title":"Blood"},{"key":"161_CR18","doi-asserted-by":"publisher","first-page":"9130","DOI":"10.1200\/JCO.2005.01.4092","volume":"23","author":"J Nuver","year":"2005","unstructured":"Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005;23:9130\u20137.","journal-title":"J Clin Oncol"},{"key":"161_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1097\/CAD.0b013e3283100e9c","volume":"19","author":"M Jafri","year":"2008","unstructured":"Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anti-Cancer Drugs. 2008;19:927\u20139.","journal-title":"Anti-Cancer Drugs"},{"key":"161_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02788.x","volume":"5","author":"D Lechner","year":"2007","unstructured":"Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy- induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost. 2007;5:24452452.","journal-title":"J Thromb Haemost"},{"key":"161_CR21","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1200\/JCO.2008.16.1109","volume":"26","author":"C Fotopoulou","year":"2008","unstructured":"Fotopoulou C, duBois A, Karavas AN, Trappe R, Aminossadati B, Schmalfeldt B, Pfisterer J, et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum\/paclitaxel containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian cancer study group. J Clin Oncol. 2008;26:2683\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"161_CR22","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/annonc\/mdp597","volume":"21","author":"KP Dieckmann","year":"2010","unstructured":"Dieckmann KP, Gerl A, Witt J, Hartmann JT, German Testicular Cancer Study Group. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21(8):1607\u201311.","journal-title":"Ann Oncol"},{"key":"161_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1160\/TH15-08-0686","volume":"117","author":"AT Cohen","year":"2017","unstructured":"Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost. 2017;117:57\u201365.","journal-title":"Thromb Haemost"},{"key":"161_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","volume":"24","author":"AA Khorana","year":"2006","unstructured":"Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24:484\u201390.","journal-title":"J Clin Oncol"},{"issue":"6","key":"161_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654\u20136.","journal-title":"J Clin Oncol"},{"key":"161_CR26","unstructured":"NCCN guidelines (Cancer-associated venous thromboembolic disease). Available at: \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf\n                    \n                  . Accessed on 02 April 2017."},{"key":"161_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11239-010-0509-x","volume":"3","author":"H Abdel-Razeq","year":"2011","unstructured":"Abdel-Razeq H, Albadainah F, Hijjawi S, Mansour A, Treish I. Venous Thromboembolism (VTE) in hospitalized cancer patients: prophylaxis failure or failure to Prophylax. J Thromb Thrombolysis. 2011;3:107\u201312.","journal-title":"J Thromb Thrombolysis"},{"key":"161_CR28","doi-asserted-by":"publisher","unstructured":"Abdel-Razeq H, Mansour A, Saadeh SS, Abu-Nasser M, Makoseh M, Salam M, et al. The application of current proposed venous Thromboembolism risk assessment model for ambulatory patients with cancer. Clin Appl Thromb Hemost. 2017:1076029617692880. \n                    https:\/\/doi.org\/10.1177\/1076029617692880.","DOI":"10.1177\/1076029617692880."},{"key":"161_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1479-5876-9-179","volume":"9","author":"S Barni","year":"2011","unstructured":"Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandal\u00e0 M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.","journal-title":"J Transl Med"},{"key":"161_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","volume":"366","author":"G Agnelli","year":"2012","unstructured":"Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601\u20139.","journal-title":"N Engl J Med"},{"key":"161_CR31","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","volume":"48","author":"A Maraveyas","year":"2012","unstructured":"Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283\u201392.","journal-title":"Eur J Cancer"},{"key":"161_CR32","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","volume":"33","author":"U Pelzer","year":"2015","unstructured":"Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33:2028\u201334.","journal-title":"J Clin Oncol"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-018-0161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T20:32:11Z","timestamp":1551385931000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-018-0161-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1186\/s12959-018-0161-9","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]},"assertion":[{"value":"6 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by our Institutional Review Board and consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"2"}}